• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Regenerative Medicine

BioCardia files 2nd FDA IDE bid for CardiAMP chronic myocardial ischemia, refractory angina study

January 5, 2018 By Fink Densford

BioCardia

BioCardia (NSDQ:BCDA) said today it filed for a second FDA investigational device exemption to launch a trial of its CardiAMP cell therapy for treating chronic myocardial ischemia and refractory angina as it seeks a second indication. The San Carlos, Calif.-based company’s CardiAMP therapy uses autologous cells to treat chronic myocardial ischemia, and is designed to stimulate […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Regenerative Medicine Tagged With: BioCardia

These lab-grown blood vessel replacements could benefit dialysis patients

January 3, 2018 By Danielle Kirsh

blood-vessels-on-shelf

University of Minnesota researchers have developed a blood vessel replacement made of biological materials in a lab. The lab-grown vessels have no living cells at implantation and could be used as a graft for kidney dialysis patients. The lab-engineered blood vessel replacement is the first nonsynthetic, decellularized graft that is repopulated with cells using the […]

Filed Under: Featured, Implants, Regenerative Medicine, Research & Development Tagged With: kidney dialysis, medtech, University of MInnesota

Histogenics inks deal to develop Neocart for the Japanese market

December 22, 2017 By Sarah Faulkner

Histogenics

Histogenics (NSDQ:HSGX) has inked a deal with Medinet to develop and commercialize its Neocart implant for the Japanese market. The Waltham, Mass.-based company’s Neocart implant is designed to repair knee cartilage damage. The product is made using a patient’s own cells, harvested from the surface of the patient’s femur. “This transformative collaboration for Histogenics is […]

Filed Under: Featured, Orthopedics, Pain Management, Regenerative Medicine, Wall Street Beat Tagged With: histogenics, medinet

Researchers reverse diabetes in mice by infusing them with blood stem cells

November 17, 2017 By Sarah Faulkner

diabetes cell therapy

Researchers at Boston Children’s Hospital successfully reversed Type I diabetes in a mouse model using blood stem cells, according to a study published this week in Science Translational Medicine. The researchers used cells that were pre-treated to make more of a protein, PD-L1, which is deficient in mice and people with Type I diabetes. “There’s really […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Regenerative Medicine, Research & Development, Stem Cells Tagged With: Boston Children's Hospital

Orthocell wins CE Mark for CelGro device

November 13, 2017 By Sarah Faulkner

OrthoCell

Orthocell (ASX:OCC) said today that its CelGro collagen medical device won CE Mark approval for a range of dental bone and soft tissue regeneration procedures. The company said it’s in talks with the strategic commercial partners to distribute its product throughout Europe and other key regions. Orthocell is also reportedly holding discussions with key opinion leaders […]

Filed Under: Featured, Regenerative Medicine, Regulatory/Compliance, Wall Street Beat Tagged With: Orthocell

Avita Medical aims for $13m to bring ReCell burn injury device to U.S.

October 11, 2017 By Sarah Faulkner

Avita Medical

Avita Medical (ASX:AVH) said today that it hopes to raise $13.2 million to fund its efforts to bring its ReCell autologous cell harvesting device for treatment of burn injuries to the U.S. The Australia-based company said it received commitments from investors for a $3.5 million private placement. Avita added that it plans to undertake a rights […]

Filed Under: Featured, Funding Roundup, Regenerative Medicine, Wall Street Beat, Wound Care Tagged With: avitamedical

Smart bandage releases medication as needed

October 10, 2017 By Sarah Faulkner

Smart bandage

A team of researchers from the University of Nebraska, Harvard Medical School and MIT have created a smart bandage that can be loaded with antibiotics, painkillers or other drugs and triggered by a smartphone. The bandage, made of electrically conductive fibers individually coated in a drug-loaded hydrogel, could be used to deliver multiple drugs at […]

Filed Under: Drug-Device Combinations, Featured, Regenerative Medicine, Research & Development, Wound Care Tagged With: Harvard University, Massachusetts Institute of Technology, universityofnebraska

MiMedx closes Stability Biologics sale

October 6, 2017 By Sarah Faulkner

MiMedx

MiMedx (NSDQ:MDXG) said this week that it completed the divestiture of its subsidiary, Stability Biologics, back to the former stockholders of Stability, Inc. The deal, which closed on Sept. 30, included a promissory note issued by Stability Biologics for $3.5 million in favor of MiMedx. “When we signed the definitive agreement for the divestiture, we communicated […]

Filed Under: Featured, Regenerative Medicine, Surgical, Wall Street Beat Tagged With: mimedx

FDA expands protocol for investigational ReCell burn injury device

October 4, 2017 By Sarah Faulkner

Avita Medical

Avita Medical (ASX:AVH) said today that the FDA approved a supplement to the company’s investigational device exemption for its ReCell autologous cell harvesting device. The approved treatment protocol for burn injuries has been simplified, according to the company, and the number of approved investigational sites has grown from eight to 15. Up until now, treatment using […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regenerative Medicine, Wall Street Beat, Wound Care Tagged With: avitamedical

Avita Medical submits PMA app for ReCell burn injury treatment

September 28, 2017 By Sarah Faulkner

Avita Medical

Avita Medical (ASX:AVH) said today that it submitted its pre-market approval application to the FDA for its ReCell autologous cell harvesting device. The company’s system is designed to reduce the amount of skin harvesting needed to treat burn injuries compared to conventional treatments. The PMA application is supported by clinical data from two trials. The […]

Filed Under: Clinical Trials, Featured, Food & Drug Administration (FDA), Regenerative Medicine, Wound Care Tagged With: avitamedical

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 7
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS